We are live on ! Find out more
NVCT icon

Nuvectis Pharma
NVCT

37 hedge funds and large institutions have $20M invested in Nuvectis Pharma in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,250% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 2

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

216% more capital invested

Capital invested by funds: $6.34M → $20M (+$13.7M)

208% more funds holding

Funds holding: 12 → 37 (+25)

4.63% more ownership

Funds ownership: 3.19% → 7.83% (+4.6%)

Holders
37
Holders Change
+25
Holders Change %
+208.33%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
8
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.8M
2
State Street
State Street
Massachusetts
+$1.47M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.24M
4
JMFC
J.M. Forbes & Co
Massachusetts
+$1.07M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
BWP
Baldwin Wealth Partners
Massachusetts
-$858K
2
Millennium Management
Millennium Management
New York
-$323K
3
Jane Street
Jane Street
New York
-$145K
4
EDRH
Edmond de Rothschild Holding
Switzerland
-$27.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$5.02M +$4.8M +300,935 +2,220%
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.25M +$1.03M +64,505 +32%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$1.8M +$1.24M +77,514 +221%
State Street
4
State Street
Massachusetts
$1.68M +$1.47M +91,840 +685%
BWP
5
Baldwin Wealth Partners
Massachusetts
$1.44M -$858K -53,739 -37%
JMFC
6
J.M. Forbes & Co
Massachusetts
$1.07M +$1.07M +67,000 New
Northern Trust
7
Northern Trust
Illinois
$857K +$856K +53,634 New
Marshall Wace
8
Marshall Wace
United Kingdom
$667K +$667K +41,775 New
Renaissance Technologies
9
Renaissance Technologies
New York
$581K +$581K +36,400 New
Citadel Advisors
10
Citadel Advisors
Florida
$448K +$447K +28,028 New
EDRH
11
Edmond de Rothschild Holding
Switzerland
$364K -$27.9K -1,750 -7%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$306K +$306K +19,150 New
Charles Schwab
13
Charles Schwab
California
$287K +$287K +17,995 New
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$200K +$176K +11,012 New
N
15
Nuveen
North Carolina
$170K +$170K +10,669 New
RhumbLine Advisers
16
RhumbLine Advisers
Massachusetts
$108K +$108K +6,778 New
New York State Common Retirement Fund
17
New York State Common Retirement Fund
New York
$91K +$91K +5,700 New
JP Morgan Chase
18
JP Morgan Chase
New York
$87.2K +$87.2K +5,460 New
Morgan Stanley
19
Morgan Stanley
New York
$81.5K +$31.7K +1,988 +64%
UBS Group
20
UBS Group
Switzerland
$63.5K +$63.5K +3,979 New
MIM
21
MetLife Investment Management
New Jersey
$63.4K +$63.4K +3,970 New
AIG
22
American International Group
New York
$52.7K +$52.6K +3,298 New
HCM
23
Hollencrest Capital Management
California
$48.5K +$48.5K +3,040 New
Wells Fargo
24
Wells Fargo
California
$45.4K +$45K +2,820 +11,280%
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$43K +$43K +2,692 New
1
2

NVCT Hedge Fund Activity: Q2 2023 in Review

37 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2023, worth a combined $20M — up 216% from $6.34M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new NVCT positions and 2 closed out — a net gain of 25 holders — while 8 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $4.8M. The largest seller was Baldwin Wealth Partners, cutting an estimated $858K.

  • 37 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2023, up from 12 in Q1 2023.
  • Funds reported $20M of Nuvectis Pharma stock for Q2 2023, up 216% quarter-over-quarter.
  • 27 funds opened new Nuvectis Pharma positions in Q2 2023 and 2 closed out, a net change of +25 holders.
  • The largest Nuvectis Pharma buyer in Q2 2023 was BlackRock, an estimated $4.8M added.
  • The largest Nuvectis Pharma seller in Q2 2023 was Baldwin Wealth Partners, an estimated $858K sold.

Based on aggregated 13F filings for Q2 2023.